Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 26 May 2018
At a glance
- Drugs Palbociclib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
- 20 Dec 2017 Planned End Date changed from 30 Jun 2018 to 17 Jul 2018.
- 20 Dec 2017 Planned primary completion date changed from 1 Jul 2017 to 17 Jul 2018.